1. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78. 2. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-6. 3. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical and molecular features and differential diagnosis. Virchows Arch 2001;438:1-12. 4. Fletcher CDM, Berman J, Corless C, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65. 5. Landi B, Lecomte T, Berger A, Cellier C Traitement des tumeurs stromales digestives. Gastroenterol Clin Biol 2004;28:893-901. 6. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate. Eur J Cancer 2003;39:2012-20. 7. Lassau N, Lamuraglia M, Leclere J, Rouffiac V. Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol. 2004 ;85 :704-12. 8. Le Cesne A, Landi B, Bonvalot S et al. Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales. Hépato-Gastro 2005 ; 5 : 377-9. 9. Plaat BE, Hollema H., Molenaar W.M., et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-20. 10. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3. 11. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al.Efficacy and safety of imatinib in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80. 12. Verweij J, Casali PG, J Zalcberg J, Le Cesne A, Reichard P, Blay JY, et al.Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.. Lancet 2004;364:1127-34. 13. RS Benjamin, C Rankin, C Fletcher, C Blanke, M Von Mehren, R Maki, et al. Phase III doserandomized study of imatinib mesylate (Glivec, STI571) for GIST : Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003;22:a3271(abstract). 14. Savage DG, Antman KH. Imatinib- a new oral targeted therapy. N Engl J Med. 2002 Feb 28;346(9):683-93 15. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int 2006;56:1-9 16. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-89. 17. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68. 18. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005;103:821-9. 19. Dematteo RP, Lewis JJ, Leung D, Mudan S, Woodruff JM, Brennen M. Two hundred gastrointestinal stromal tumors : recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-8. 20. Fayette J, Méeus P, Ray-Coquard I, et al. Traitement médical des tumeurs stromales gastro-intestinales localisées et avancées : standards thérapeutiques en 2006. Bull Cancer 2006 : 93 ; S173-180. 21. Rouquié D, Bonvalot S. Chirurgie des tumeurs stromales gastro-intestinales aux stades localisé et métastatique. Bull Cancer 2006 : 93 ; S167-72. 22. Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, Bonvalot S. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004;30:1098-103 23. Bonvalot S, Eldweny H, Le Pechoux C, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N, Le Cesne A. Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era. Ann Surg Oncol 2006 Sep 7 [Epub ahead of print] 24. Adam R, Bonvalot S, Vibert E, Le Cesne A. Métastases hépatiques des sarcomes et tumeurs stromales. In Chirurgie des métastases hépatiques des cancers non colorectaux non endocrines. Rapport présenté au 107ème congrès de l’AFC. Monographie de l’Association Française de Chirurgie 2005. Editions Arnette. p 279-302. 25. Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005;117:316-25 26. Rutkowski P, Nowecki Z, Dziewirski W, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93:304-11 27. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-31. 28. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103. 29. Zalcberg JR, Verweij J, Casali PG, J, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005 ;41:1751-7 30. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35. 31. Casali PG, Garrett CR, Blackstein ME et al . Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. Proc Am Soc Clin Oncol 2006; 25, A9513 (abstract). 32. Heinrich MC, Maki RG, Corless CL et al. Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFRA mutation status. Proc Am Soc Clin Oncol 2006;25, A9502 (abstract). 33. Demetri GD, Van Oostreom AT, Blackstein M et al. Phase III multicenter randomized double blind placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol 2005; 24, A 4000 (abstract).